WorldCare Clinical Commences Phase III Clinical Trial for Treatment of Soft Tissue Sarcoma
Boston, MA, May 28, 2017--
WorldCare Clinical (WCC), a leading provider of imaging services in Oncology clinical trials, today announced that it had commenced imaging services on a Phase III international clinical trial to assess a new treatment for soft tissue sarcoma.
Soft tissue sarcoma is a rare cancer that occurs in the body’s soft tissue (muscles, fat, blood vessels, tendons, fibrous tissues and synovial tissues). About 40 percent of the diagnoses occur in the legs, usually at or above the knee. Soft tissue sarcomas can metastasize to other organs of the body. Each year, approximately 3,900 people in the United States die from the disease.
In the current clinical trial, WCC is working with sites in the United States, Europe, and Asia to acquire MR images of the knee area. These MR images are then assessed using state-of-the-art analysis software by board-certified radiologists from Harvard Hospitals who specialize in sarcoma diagnosis.
WCC’s approach to rare cancers is consistent with its approach to other rare diseases such as beta thalassemia and adrenoleukodystrophy. “We leverage our large network of clinical affiliations to access subspecialty experts whose acumen allow us to maximize the accuracy of the assessment. This is complemented by our experienced scientific and operational team, ensuring high-quality results and a smooth trial,” stated Aaron Timm, CEO of WorldCare Clinical.
About WorldCare Clinical
WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC’s robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.
For more information on WCC's services, please visit our website at worldcareclinical.com or contact: